Literature DB >> 8759185

Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients.

G Leibowitz1, A Tsur, S D Chayen, M Salameh, I Raz, E Cerasi, D J Gross.   

Abstract

OBJECTIVE: Autonomous cortisol secretion without clinical stigmata of Cushing's syndrome (CS) has been recently recognized and termed pre-clinical or sub-clinical CS. The common assumption is that CS is an extremely rare cause of uncontrolled diabetes; however, the prevalence of this entity has not been studied. We assessed the prevalence of pre-clinical CS among obese patients with uncontrolled diabetes. PATIENTS AND
DESIGN: (1) In a retrospective analysis, the medical records of 63 patients with endogenous CS were reviewed. (2) In a cross-sectional study, 90 obese patients (BMI > 25 kg/m2) followed in a University Hospital and the local Health Fund endocrine and diabetes clinics, with poorly controlled diabetes (glycosylated haemoglobin > 9%), underwent an overnight 1 mg dexamethasone suppression. In patients with non-suppressible cortisol levels (> 140 nmol/l), Liddle's 2 and 8 mg dexamethasone suppression tests and imaging studies were performed. MEASUREMENTS: The prevalence of poorly controlled diabetes, the major presenting symptom of CS, was assessed in the retrospective analysis. The prevalence of "true' CS and the false positive rate in the overnight dexamethasone suppression test were calculated. The endocrine evaluation of the patients with pre-clinical CS and the effects of surgical cure on glycaemic control are described.
RESULTS: In the retrospective analysis, 11 (17.5%) had diabetes and 2 (3.2%) lacked the classic physical characteristics of the syndrome. In the cross-sectional study, 4 patients failed to suppress plasma cortisol (< 140 nmol/l). In one patient the diagnosis of CS was not confirmed by a standard Liddle's test and was therefore considered false positive. In the other 3, the diagnosis of CS was confirmed (prevalence of 3.3%, 95% confidence interval 1-9%). In all other patients the overnight cortisol suppression test was normal (cortisol level 47.3 +/- 2.5 nmol/l (mean +/- SEM)). After surgical treatment of CS, glycaemic control was markedly improved in all 5 patients (2 from retrospective and 3 from cross-sectional studies).
CONCLUSIONS: The prevalence of pre-clinical Cushing's syndrome in obese patients with poorly controlled diabetes appears to be considerably higher than previously believed. The overnight dexamethasone suppression test proved to be a simple, sensitive and highly specific screening test for Cushing's syndrome despite the presence of obesity and hyperglycaemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759185     DOI: 10.1046/j.1365-2265.1996.737558.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

1.  Raised cortisol excretion rate in urine and contamination by topical steroids.

Authors:  C J Kelly; A Ogilvie; J R Evans; D Shapiro; A M Wallace; D L Davies
Journal:  BMJ       Date:  2001-03-10

2.  Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Liudmila Y Rozhinskaya; Natalia V Dragunova; Larisa K Dzeranova; Svetlana A Butrova; Ekaterina A Troshina; Ivan I Dedov
Journal:  Endocrine       Date:  2012-03-25       Impact factor: 3.633

Review 3.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 4.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

5.  Cushing's syndrome: all variants, detection, and treatment.

Authors:  Susmeeta T Sharma; Lynnette K Nieman
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 6.  Glucose metabolism in patients with subclinical Cushing's syndrome.

Authors:  Roberta Giordano; Federica Guaraldi; Rita Berardelli; Ioannis Karamouzis; Valentina D'Angelo; Elisa Marinazzo; Andreea Picu; Ezio Ghigo; Emanuela Arvat
Journal:  Endocrine       Date:  2012-03-06       Impact factor: 3.633

7.  Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.

Authors:  Michael S Broder; Maureen P Neary; Eunice Chang; Dasha Cherepanov; William H Ludlam
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

8.  Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients.

Authors:  Bradley R Javorsky; Ty B Carroll; Nicholas A Tritos; Roberto Salvatori; Anthony P Heaney; Maria Fleseriu; Beverly M K Biller; James W Findling
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

9.  Midnight salivary cortisol for the diagnosis of Cushing's syndrome in a Chinese population.

Authors:  Dao-Chen Lin; Pei-Shan Tsai; Yi-Chun Lin
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

10.  Diagnostic efficacy of midnight cortisol and midnight ACTH in the diagnosis and localisation of Cushing's syndrome.

Authors:  Mathew John; Anurag R Lila; Tushar Bandgar; Padma S Menon; Nalini S Shah
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.